Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous-cell cancer of the head and neck. Otolaryngol Clin N Am. 1985 Aug 1;18(3):367-88.